Physician profile
Vincent A Ho
NPI 1124138359
$31,649.02
in general payments reported to CMS, 2019-2025
61 companies · $3,935 in 2025
The $3,935 reported for 2025 was more than what 97% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,122 · 2020: $3,054 · 2021: $4,596 · 2022: $5,348 · 2023: $4,133 · 2024: $4,461 · 2025: $3,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,354.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,754.66 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $3,381.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,528.34 | 2019-2025 | |
| Amgen INC. | $2,464.19 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $2,389.29 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,297.26 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Gilead Sciences, INC. | $1,742.49 | 2019-2025 | Epclusa |
| Sanofi-Aventis U.S. LLC | $1,626.55 | 2019-2025 | |
| Lilly USA, LLC | $1,616.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $982.27 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $674.40 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $651.79 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $626.49 | 2019-2022 | |
| Pfizer INC. | $527.10 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.58 | 2019-2024 | Xifaxan |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.